Both in Biotechnology
Anavex Life Sciences vs Humacyte
Over the past year AVXL returned −84.5% and HUMA returned −72.3%; their daily moves had a correlation of 0.21.
AVXL −84.5% HUMA −72.3%Growth of $1, one year, split-adjusted
| Metric | AVXL | HUMA |
|---|---|---|
| Price | $1.20 | $0.4405 |
| Market cap | $111.2M | $122.4M |
| Today | +5.26% | +10.65% |
| 1 month | −27.1% | −11.9% |
| 6 months | −64.3% | −51.2% |
| Year to date | −66.3% | −54.1% |
| 1 year | −84.9% | −73.6% |
| Revenue growth (YoY) | — | +34.9% |
| Gross margin | — | −203.2% |
| Net margin | — | −9064.5% |
| P/E (TTM) | — | — |
| Price / sales | — | 57.7× |
| Net cash | $118.3M | $13.7M |
| Dividend yield | — | — |
| Volatility (60d) | 74.0% | 108.0% |
| Short % of float | 14.0% | 11.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).